Agios Pharmaceuticals Inc. (AGIO)
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q3 2024 Earnings Conference Call October 31, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Greg Harrison - Scotiabank Alex Nackenoff - Raymond James Greg Renza - RBC Capital Markets Eric Schmidt - Cantor Fitzgerald Chris Raymond - Piper Sandler Tessa Romero - JPMorgan Divya Rao - TD Cowen Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Andrew Berens - Leerink Partners Operator Good morning, and welcome to Agios' Third Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today's call is being recorded at Agios' request.
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with quarterly earnings of $4.20 per share, missing the Zacks Consensus Estimate of $16.69 per share. This compares to loss of $1.64 per share a year ago.
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Agios' Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 trials showing positive results for hemoglobin improvement. Expanding Pyrukynd's label to include pediatric and thalassemia indications is crucial, with regulatory filings expected by 2025.
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides
On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to
Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Christopher Raymond - Piper Sandler Gregory Renza - RBC Capital Markets Divya Rao - TD Cowen Tess Romero - JP Morgan Alec Stranahan - Bank of America Operator Good morning, and welcome to Agios' Second Quarter 2024 Conference Call. [Operator Instructions].
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1.51 per share a year ago.
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study
Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
Agios Pharmaceuticals said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study.
